• 1. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 2. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 3. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 4. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 5. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Fluorobenzenes

Recent Advances in the Study of 3-(3-Fluorophenyl)prop-2-ynoic acid (CAS: 705-83-9)

3-(3-Fluorophenyl)prop-2-ynoic acid (CAS: 705-83-9) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential applications in drug discovery and development. This compound, characterized by its fluorophenyl and propynoic acid moieties, exhibits unique chemical properties that make it a promising candidate for various therapeutic interventions. Recent studies have explored its role as a building block in the synthesis of novel bioactive molecules, particularly in the context of targeting enzyme inhibition and modulating protein-protein interactions.

A study published in the Journal of Medicinal Chemistry (2023) investigated the inhibitory effects of 3-(3-Fluorophenyl)prop-2-ynoic acid on histone deacetylases (HDACs), a class of enzymes implicated in cancer progression. The researchers utilized a combination of molecular docking and kinetic assays to demonstrate that this compound exhibits selective inhibition against HDAC6, with an IC50 value of 1.2 μM. This finding suggests its potential as a lead compound for the development of HDAC6-specific inhibitors, which could offer new avenues for cancer therapy with reduced off-target effects.

Another significant advancement was reported in ACS Chemical Biology (2024), where 3-(3-Fluorophenyl)prop-2-ynoic acid was employed as a key intermediate in the synthesis of covalent inhibitors for ubiquitin-specific proteases (USPs). The study highlighted the compound's ability to form stable covalent adducts with the active-site cysteine residues of USPs, thereby blocking their enzymatic activity. This approach has shown promise in preclinical models of neurodegenerative diseases, where USP dysfunction is a contributing factor.

In addition to its therapeutic potential, recent research has also focused on the pharmacokinetic properties of 3-(3-Fluorophenyl)prop-2-ynoic acid. A pharmacokinetic profiling study (European Journal of Pharmaceutical Sciences, 2023) revealed that the compound exhibits favorable oral bioavailability and metabolic stability in rodent models. These findings support its further development as a drug candidate, although additional studies are needed to assess its safety profile and potential toxicity.

Overall, the latest research underscores the versatility of 3-(3-Fluorophenyl)prop-2-ynoic acid (CAS: 705-83-9) in chemical biology and drug discovery. Its unique structural features and demonstrated bioactivity make it a valuable tool for exploring new therapeutic targets and mechanisms. Future studies are expected to delve deeper into its applications, particularly in the context of personalized medicine and targeted therapies.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)